Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00177164
Other study ID # RIS-PSY-405
Secondary ID Univ. Pittsburgh
Status Completed
Phase Phase 3
First received September 12, 2005
Last updated January 7, 2016
Start date November 2003
Est. completion date December 2009

Study information

Verified date January 2016
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

We recruited 50 consenting adult subjects with DSM-IV TR diagnoses of bipolar disorder who were about to initiate or switch their current antipsychotic agent. Patients were titrated and cross-tapered during a 3 month titration and stabilization phase. They were followed for an additional 12 months. Clinical outcomes such as study drop out, adverse events, worsening of symptoms, crisis interventions, need for additional medication, hospitalizations etc. were evaluated from months 3 to 15. The numbers of clinical events (pooled) will be used to evaluate if the long acting injectable form of risperidone has an advantage over the oral second generation antipsychotic agents in terms of treatment continuity and clinical stability.


Description:

OBJECTIVE:

To evaluate if a long acting injectable form of risperidone offers clinical advantages over comparison oral second generation antipsychotic agents following titration and stabilization in bipolar subjects. In keeping with current practice, it is expected the vast majority of patients will also be receiving either lithium or valproate or other anticonvulsants. Following the stabilization phase several clinical events will be evaluated for up to 15 months in the two treatment groups to examine differences in clinical outcomes between those receiving the injectable versus oral medicines.

RESEARCH PLAN:

We intend to recruit 50 consenting adult subjects with DSM-IV TR diagnoses of bipolar disorder who are about to initiate or to switch their antipsychotic agent. Patients will be titrated and cross-tapered during a 3 month titration and stabilization phase. Those who transition successfully and show some improvement will be followed for an additional 12 months. Clinical outcomes such as study drop out, adverse events, worsening of symptoms, crisis interventions, need for additional medication, hospitalizations etc. will be evaluated from months 3 to 15. The numbers of clinical events (pooled) will be used to evaluate if the long acting injectable form of risperidone has an advantage over the oral second generation antipsychotic agents in terms of treatment continuity and clinical stability.

METHODS:

An open design, but treatment to either the long acting risperidone or to the oral second generation antipsychotic agents is randomly assigned. A board independent of the day-to-day clinical events will code the primary clinical outcomes of interest without knowledge of treatment assignment. The board will be provided clinical summaries of these events without revealing the treatment assignment.

SIGNIFICANCE:

The use of a long acting injectable second generation antipsychotic agent may offer advantages of treatment continuity and adherence in bipolar patients permitting improved clinical stability and improved psychosocial and functional outcomes. Such stability is difficult to achieve in the face of frequent treatment discontinuations seen with oral agents. The improved tolerability of the second generation antipsychotic agents may change the perception of long acting injections. For instance, these agents are likely to be more acceptable to patients, families and clinicians and therefore likely be used much sooner in the treatment algorithms of bipolar patients than in the past. This study will provide a treatment effect size to statistically power future comparisons of long-acting injectable vs. oral antipsychotic agents in persons with bipolar disorder


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 2009
Est. primary completion date March 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- DSM-IV - TR diagnoses of bipolar disorder (I or II or NOS).

- Age 18 to 70 years

- Men or women

- Any Ethnicity

- Currently receiving or willing to receive treatment at sites associated with the Western Psychiatric Institute and Clinic -University of Pittsburgh Medical Center (inpatient or ambulatory) or Mon Yough Community Services, Inc. or at Mayview State Hospital, Bridgeville, PA (inpatient)

- Able to provide competent and sign an informed consent document

- It is clinically appropriate in the eligible individual to consider antipsychotic treatment for at least 15 months (clinician and investigator determined)

- It is clinically appropriate to switch antipsychotic treatment to one of the second generation antipsychotic agents being evaluated in this study.

- There is no known contraindication for the use of either risperidone or for more than two of the antipsychotic agents being considered in the study (Investigator determined)

- At entry (at the screening visit, and just prior to randomization) Y-MRS (Young-Mania rating scale, Young et al., 1978) total score > 15 in bipolar disorder patients entering in a manic or mixed or hypomanic or NOS episode.

- Either life-time or current comorbid substance abuse or dependence is permitted (unless the Investigator and referring physician opines the substance abuse is likely to significantly interfere with either the diagnosis of the Axis I condition or to compromise patients safety due to withdrawal issues (Investigator determined).

- Screening physical and laboratory/EKG procedures are within acceptable limits

Exclusion Criteria:

- Actively suicidal or dangerous to others (Investigator opines that it is inappropriate to involve the potential subject in the study)

- Pregnant or lactating women

- Women in the reproductive age group who are not using any acceptable contraception (abstinence is not acceptable) or intend to become pregnant during the trial

- Subjects who are likely to face incarceration during the study duration (and for those already in the study, the continued participation of such subjects will be evaluated on a case-by-case basis)

- Patients currently receiving clozapine (or within six weeks prior to randomization) are ineligible for the study

- Subjects currently receiving a depot neuroleptic injectable agent, or within 2 injection cycles of receiving the injection prior to randomization.

- Allergy or serious side effects (for instance - neuroleptic malignant syndrome) to either risperidone or to more than two of the other second-generation antipsychotic agents that have been approved for use in the U.S.A. (olanzapine, quetiapine, ziprasidone, aripiprazole-per investigator and referring clinician).

- Treatment resistance to either risperidone, or to more than two of the other antipsychotic agents in this trial (olanzapine, quetiapine, ziprasidone, aripiprazole).

- This is the first episode of mania, mixed or hypomania for patients.

- Current (or within one month prior to randomization) participation in an investigational drug/device study.

- Currently participating in another study that would confound the present study objectives (per investigator)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Injectable Risperidone (Consta) or oral antipsychotic
Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder

Locations

Country Name City State
United States Mayview State Hospital Bridgeville Pennsylvania
United States Dubois Regional Medical Center Dubois Pennsylvania
United States Mon-Yough Community Services, Inc. McKeesport Pennsylvania
United States Western Psychiatric Institute and Clinic Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pittsburgh Janssen Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (1)

Chengappa KN, Turkin SR, Schlicht PJ, Murphy SL, Brar JS, Fagiolini A, Houck PR, Garbutt RG, Fredrick N. A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in perso — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive Either Risperidal Consta or One of the 4 Marketed 2nd Generation Antipsychotic Agents. Upto 15 months No
Secondary Evaluate Differences in Types of Clinical Events Between the Two Randomized Groups,and Differences if Any Between the Two Treatment Groups in Terms of Weight Gain, Dyslipidemia, Hyperglycemia Etc. Upto 15 months Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Withdrawn NCT01495156 - Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Phase 4
Completed NCT00982020 - Study in Adolescents With Schizophrenia or Bipolar Disorder Phase 4
Completed NCT00746343 - Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study N/A
Completed NCT00177463 - L-Carnosine for Bipolar I Disorder N/A
Completed NCT03257865 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Phase 3
Completed NCT03259555 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Phase 3
Not yet recruiting NCT06433635 - Sequential Multiple Assignment Randomized Trial for Bipolar Depression Phase 4
Completed NCT04127058 - Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia Phase 1
Recruiting NCT05977023 - NMDA Receptor Modulation for the Treatment of Bipolar I Disorder Phase 2
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Completed NCT03287869 - A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. Phase 3
Enrolling by invitation NCT04987229 - Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Phase 3
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Completed NCT00232414 - A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder Phase 3
Completed NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Phase 1
Active, not recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Recruiting NCT03943537 - Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Phase 2
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3